Anticancer
The biotech’s Phase III data with an oncolytic immunotherapy for non-muscle invasive bladder cancer shows high complete response rates, duration of response and good safety/tolerability.
The MMRF aims to incorporate a variety of new bispecific antibodies, cell therapies, checkpoint inhibitors and novel small molecules into the Horizon study.
The company is keeping up a flow of deals in oncology, opening up access to a range of new modalities and potential future combinations with two new tie-ups.
Former Roche CEO Bill Burns reflects on transforming Roche into a global leader in specialty care and oncology. Now, as he spearheads efforts to combat antibiotic resistance, Burns shares insights on industry evolution, the power of cultural change, and the urgent need for a new business model in antibiotics development.
Deal Snapshot: Gilead will pay $20m up front to the German biotech to develop an antibody-drug conjugate with a topoisomerase-1 payload meant to address durability and safety challenges.
The company’s CD40 agonist mitazalimab has impressed in Phase II trials as a potential treatment for pancreatic cancer but with no partner in place yet and a lack of funds, Alligator has to cut 70% of its staff to keep going.
The Chinese company is building on its success with ivonescimab and believes it can stay ahead of its rivals and develop into a global company.
The Norwegian biotech is losing a big pharma partner and up to half of its staff, but remains confident about the prospects for its personalized cancer vaccine programs.
Ahead of ASH 2024, Ichnos Glenmark Innovation’s CEO outlines to Scrip the promising profile of the alliance’s early stage trispecific versus existing bispecific antibodies in relapsed/refractory multiple myeloma, including a significant overall response rate.
The SKYSCRAPER-01 trial’s failure to generate an overall survival benefit is the biggest blow yet to the TIGIT inhibitor class, but Roche looking to move on with its buyout of the CAR-T therapy company.
The Swiss major’s chief medical officer tells Scrip about how “an R&D/commercial continuum” is helping to speed up innovation across the group.
Analysts are hoping for a sizeable benefit on PFS when the full data emerge.
Billion dollar-plus global deal with Japanese partner gives Kura's lead asset development impetus while adding to Kyowa Kirin's ambitions in hematological malignancies.
The agency granted accelerated approval to zanidatamab in HER2-positive biliary tract cancer, though the company is eyeing larger indications for the drug.
Asia-Pacific continues to solidify its position as a key location for clinical trials, with China in particular dominating such activity in the region, and increasingly globally, a new Citeline White Paper shows.
The new formulation is expected to play a role in helping Merck maintain its multibillion-dollar cancer franchise after Keytruda loses exclusivity in 2028.
The drug maker anticipates a potential label expansion for Revuforj (revumenib) from KMTA2-translocation acute leukemias into NPM1-mutant AML.
Dosing eftilagimod alpha on top of Merck & Co’s blockbuster appears to improve survival, though more robust data are needed.
The company will in-license LM-299, gaining a PD-1/VEGF bispecific antibody that could help it defend its blockbuster PD-1 franchise against looming competition.
Analysts had hoped a prior negative result in acute myeloid leukemia would not read through to Syros’s Phase III myelodysplastic syndrome study, but SELECT-MDS-1 nevertheless failed too.